1. Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease
- Author
-
Sabine Sarnacki, Anne-Sophie Gille, Corinne Pondarré, Françoise Bernaudin, Jean-Hugues Dalle, Lydia Riou, Eva Maria Comperat, Pierre Fouchet, Bénédicte Neven, Catherine Patrat, Annabel Paye-Jaouen, Saba Azarnoush, Cécile Arnaud, Céline Chalas, Camille Jean, Nathalie Dhedin, Mariane de Montalembert, Mathilde Sibony, Jean-Philippe Wolf, Gilles Lenaour, Virginie Barraud-Lange, Harry Lezeau, Daniel Vaiman, Véronique Drouineaud, Annie Kamdem, Catherine Poirot, Mony Fahd, and Karima Yakouben
- Subjects
0301 basic medicine ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,business.industry ,Immunology ,Cell ,Physiology ,Cell Biology ,Hematology ,Disease ,Affect (psychology) ,medicine.disease ,Biochemistry ,Sickle cell anemia ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Sperm cell ,Prepuberty ,Biopsy ,medicine ,business - Abstract
In these two short reports, the authors approach the issue of whether hydroxyurea (HU) use in young males has major irreversible effects on sperm production. Joseph et al analyzed and compared sperm parameters in male patients with sickle cell disease (SCD) who were exposed or not exposed to HU before puberty. They report semen abnormalities in all patients but no differences between groups. Independently, Gille et al provide evidence for the lack of in vivo HU-related decreases in the spermatogonial pool in biopsy specimens from young males with SCD but evidence for a negative effect of SCD itself. Together, these reports suggest that the use of HU in young males does not adversely affect fertility.
- Published
- 2021